top of page



Mark appears in the Top 100

Canadian Professionals Magazine

Groper, mark-logo.png

Mark Groper

As the president and chief executive officer of Orion Biotechnology, Mark Groper leads a team with a unique combination of skills and strengths. With over three decades in the health care and pharmaceutical industries in both the private and public sectors and a record of building successful fast-growth technology companies, Mark is the innovative leader of a biotech company driven by science. As CEO, his primary responsibility is to create, communicate, and oversee the successful implementation of the organization's vision, mission, and overall direction. He focuses on both the Orion’s success as a business and the company’s science that has the potential to change lives.

“My hope is that in the future ‘cancer’ will not be a word people are afraid of. Orion’s drug discovery platform has enabled the development of a new class of precision-engineered immunotherapeutic drugs that have the potential to deliver the next generation of safe and effective immunotherapies without the negative side effects of chemotherapy,” Mark says.

Mark Groper

President & Chief Executive Officer of Orion Biotechnology


About Orion Biotechnology

Orion Biotechnology is a clinical-stage pharma start-up founded in 2018 to focus on discovering and developing novel drugs for a large range of G-Protein Coupled Receptors (GPCRs) - promising targets for next generation therapies. Based in Ottawa, Ontario, the company has pioneered a new approach to precision engineering analogs of natural proteins in order to effectively target often ‘difficult to drug’ GPCRs.  In the process, Orion created a proprietary drug discovery platform that dramatically reduces the cost and time required to generate new compounds for unmet medical needs in multiple disease categories.  The company’s lead candidate – OB-002 – is a first-in-class chemokine analog, developed using the Orion discovery platform, which has shown best-in-class potency as a chemokine-chemokine receptor 5 (CCR5) antagonist. It’s a promising immunotherapeutic candidate specifically designed to overcome the limitations of current treatment modalities, with the potential to provide superior potency and safety and provide effective treatment to patients who have exhausted currently available therapeutic options. Orion’s scientific approach is unique in the industry and it is the company’s goal to deliver the next generation of GPCR targeted therapeutics for the treatment of cancer and other serious disease.  



Download the Top 100 Canadian Professionals magazine and check out Mark's feature on page 23.

bottom of page